Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication

Completed

Conditions studied: Shock

In brief

Although shock therapy is effective in terminating ventricular tachycardia (VT), it can be painful to the patient and repetitive shocks can decrease a patient's quality of life. Previous studies have suggested that one or more sets of aggressive device parameter settings may reduce the total number of shocks in primary prevention patients. In addition to shock therapies, antitachycardia pacing (ATP) is also available in ICDs to treat VT. The PROVIDE trial aims to prospectively study the effect of high detection rates, prolonged detection intervals, aggressive SVT discriminators, and extensive ATP therapy in prolonging the time to first shock in primary prevention patients.

Key facts

Study ID

NCT00743522

Run by

Abbott Medical Devices

People needed

1670

Starts

2008-09-01

Expected to finish

2011-12-01

Last updated by the study team

2019-02-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary Prevention indication for ICD/ CRT-D

You may not qualify if…

• No prior documented history of spontaneous VT/VF

Where it is running

• Hall-Garcia Cardiology Associates — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.